

## ABSTRACT

The pharmaceutical composition of the present invention comprises (1) a carbostyryl derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyryl derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

(19) World Intellectual Property  
Organization  
International Bureau



540511  
24 JUN 2005

(43) International Publication Date  
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number  
**WO 2004/060374 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/496**,  
31/381, 31/343, 31/15, 31/4525, 31/135, A61P 25/24

(21) International Application Number:  
PCT/JP2003/016724

(22) International Filing Date:  
25 December 2003 (25.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
NO. 2002-379003  
27 December 2002 (27.12.2002) JP  
60/470,481 14 May 2003 (14.05.2003) US

(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP];  
9, Kanda-Tsukasacho 2-chome, Chiyoda-ku, Tokyo  
101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIKUCHI, Tetsuro**  
[JP/JP]; 157-13, Kawauchicho Komatsunishi, Tokushima-

shi, Tokushima 771-0104 (JP). **IWAMOTO, Taro** [JP/US];  
36, Boundinot Street, Princeton, NJ 08540 (US). **HIROSE,**  
**Tsuyoshi** [JP/JP]; 8-9-502, Sakoichibancho, Tokushima-  
shi, Tokushima 770-0021 (JP).


(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New  
Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku,  
Tokyo 100-0004 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,  
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS**



(57) Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyryl derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyryl derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

WO 2004/060374 A1